Labetuzumab govitecan IMMU 130; hMN-14-SN-38|cas:1469876-18-3|西域试剂

Labetuzumab govitecan IMMU 130; hMN-14-SN-38

产品编号：Bellancom-P99681| CAS NO：1469876-18-3

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	包装	价格	库存与货期	购买量	操作
Bellancom-P99681		￥7800.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Labetuzumab govitecan IMMU 130; hMN-14-SN-38

产品介绍

Labetuzumab govitecan (IMMU 130) 是一种抗 CEACAM5/SN-38 的 抗体-活性分子偶联物 (ADC)。Labetuzumab govitecan 由抗体 Labetuzumab、SN-38 和 pH 敏感连接子组成。Labetuzumab govitecan 可用于癌症研究，如结直肠癌

生物活性

Labetuzumab govitecan (IMMU 130) is an Anti-CEACAM5/SN-38 antibody-drug conjugate (ADC). Labetuzumab govitecan consists of the antibody Labetuzumab, SN-38, and a pH-sensitive Linker. Labetuzumab govitecan can be used for research of cancers, such as colorectal cancer.

体外研究

体内研究

Labetuzumab govitecan (总共 1.0 mg，腹腔注射) 可延长 GW-39 肺转移小鼠模型的中位生存期。
Labetuzumab govitecan (25 mg/kg，腹腔注射，每周两次，持续 4 周) 可延长皮下 LS174T 异种移植裸鼠的中位生存期。

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	sc LS174T Xenograft in nude mice
Dosage:	25 mg/kg
Administration:	i.p. twice weekly for 4 weeks
Result:	Prolonged median survival.

Animal Model:	LS174T tumor xenograft model in nude mice (PK assay)
Dosage:	0.25 mg
Administration:	i.v.
Result:	T1/2: 112.5 h; C_max: 115 μg/mL; MRT: 147 h.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	sc LS174T Xenograft in nude mice
Dosage:	25 mg/kg
Administration:	i.p. twice weekly for 4 weeks
Result:	Prolonged median survival.

Animal Model:	LS174T tumor xenograft model in nude mice (PK assay)
Dosage:	0.25 mg
Administration:	i.v.
Result:	T1/2: 112.5 h; C_max: 115 μg/mL; MRT: 147 h.